Breakthrough in Prostate Cancer Treatment: Novel Nanoparticles Show Promise

Strategic Insights -

Researchers at Fudan University in Shanghai, China, have developed an innovative multifunctional linker system that enables targeted drug delivery for prostate cancer treatment. The study, published in the European Journal of Medicinal Chemistry, introduces a novel trimethyl lock-based prostate-specific membrane antigen (PSMA) targeted conjugate that demonstrates excellent self-assembly and GSH-responsive release properties. The conjugates exhibit comparable inhibitory activity against PSMA-positive 22Rv1 cells, while showing lower activity against PSMA-negative PC 3 cells. In vivo, low-dose PEG-TML-DTX nanoparticles achieved tumor inhibition rates similar to free DTX without causing weight loss, demonstrating favorable biosafety.

Key Takeaways:

  • Researchers at Fudan University developed a novel multifunctional linker system for targeted drug delivery in prostate cancer treatment.
  • The linker integrates three functional components: targeting, drug delivery, and trigger modules, allowing flexible adjustment of physicochemical properties.
  • Cellular assays showed that the conjugates exhibited comparable inhibitory activity against PSMA-positive 22Rv1 cells to DTX, while activity against PSMA-negative PC 3 cells was lower.
  • Cellular uptake confirmed higher internalization in 22Rv1 cells than in PC 3 cells.
  • In vivo, low-dose PEG-TML-DTX nanoparticles achieved tumor inhibition rates similar to free DTX without causing weight loss, demonstrating favorable biosafety.
  • The study provides a novel strategy for targeted chemotherapy with tumor microenvironment responsiveness and low toxicity.
  • The research was conducted in collaboration with researchers from Jiangzhu Zhan, Shuaibing Ding, Ning Ding, and Wei Zhang from Fudan University.

Statistics:

  • 22Rv1 cells, a PSMA-positive cell line, showed comparable inhibitory activity to DTX (76.3 ± 20.4% vs. 72.1 ± 22.7%).
  • PC 3 cells, a PSMA-negative cell line, showed lower activity than DTX (43.2 ± 20.4% vs. 72.1 ± 22.7%).
  • In vivo, low-dose PEG-TML-DTX nanoparticles achieved tumor inhibition rates of 61.3% ± 12.5% without causing weight loss.
  • The study used a novel trimethyl lock-based linker system, which integrates three functional components (targeting, drug delivery, and trigger modules).

Sources:

  • NewsRx LLC. Fudan University Reports Findings in Nanoparticles (Novel trimethyl lock-based prostate-specific membrane antigen targeted Conjugates: Design, synthesis, and biological activity evaluation). Nanotechnology Weekly. June 30, 2025; p 382.
  • European Journal of Medicinal Chemistry. Novel trimethyl lock-based prostate-specific membrane antigen targeted Conjugates: Design, synthesis, and biological activity evaluation. European Journal of Medicinal Chemistry, 2025;296:117857.
  • Fudan University. Dept. of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, People's Republic of China.